Lancet neurology

(ISSN: 1474-4422)

Table of Contents

From Lancet neurology

2021 - 20 (1)

  • Headache research in 2020: disrupting and improving practice. 
  • APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches. 
  • Advances in traumatic brain injury research in 2020. 
  • Dementia research in 2020: moving forward despite the COVID-19 pandemic. 
  • Our health-care system is failing young people with epilepsy. 
  • Jacqueline Palace: a force for good in neuroimmune disorders. 
  • Important advances in stroke research in 2020. 
  • Neurological infections in 2020: COVID-19 takes centre stage. 
  • Sleep research in 2020: COVID-19-related sleep disorders. 
  • Major advances in amyotrophic lateral sclerosis in 2020. 
  • Multiple sclerosis in 2020: un bon cru. 
  • Movement disorders in 2020: clinical trials, genetic discoveries, and COVID-19. 
  • Rapid drug access and scientific rigour: a delicate balance. 
  • Oral steroids for episodic cluster headache. 
  • Safety and efficacy of prednisone versus placebo in short-term prevention of episodic cluster headache: a multicentre, double-blind, randomised controlled trial. 
  • Are drugs for multiple sclerosis fatigue just placebos? 
  • Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial. 
  • Correction to Lancet Neurol 2020; 19: 998-1009. 
  • Patisiran in hereditary transthyretin-mediated amyloidosis. 
  • Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. 
  • New therapies for neuromyelitis optica spectrum disorder. 

Journal Information